Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public

Added by mollevi
Group name EquipeMY
Item Type Journal Article
Title TOM1L1 drives membrane delivery of MT1-MMP to promote ERBB2-induced breast cancer cell invasion
Creator Chevalier et al.
Author Clément Chevalier
Author Guillaume Collin
Author Simon Descamps
Author Heiani Touaitahuata
Author Valérie Simon
Author Nicolas Reymond
Author Laurent Fernandez
Author Pierre-Emmanuel Milhiet
Author Virginie Georget
Author Serge Urbach
Author Laurence Lasorsa
Author Béatrice Orsetti
Author Florence Boissière-Michot
Author Evelyne Lopez-Crapez
Author Charles Theillet
Author Serge Roche
Author Christine Benistant
Abstract ERBB2 overexpression in human breast cancer leads to invasive carcinoma but the mechanism is not clearly understood. Here we report that TOM1L1 is co-amplified with ERBB2 and defines a subgroup of HER2(+)/ER(+) tumours with early metastatic relapse. TOM1L1 encodes a GAT domain-containing trafficking protein and is a SRC substrate that negatively regulates tyrosine kinase signalling. We demonstrate that TOM1L1 upregulation enhances the invasiveness of ERBB2-transformed cells. This pro-tumoural function does not involve SRC, but implicates membrane-bound membrane-type 1 MMP (MT1-MMP)-dependent activation of invadopodia, membrane protrusions specialized in extracellular matrix degradation. Mechanistically, ERBB2 elicits the indirect phosphorylation of TOM1L1 on Ser321. The phosphorylation event promotes GAT-dependent association of TOM1L1 with the sorting protein TOLLIP and trafficking of the metalloprotease MT1-MMP from endocytic compartments to invadopodia for tumour cell invasion. Collectively, these results show that TOM1L1 is an important element of an ERBB2-driven proteolytic invasive programme and that TOM1L1 amplification potentially enhances the metastatic progression of ERBB2-positive breast cancers.
Publication Nature Communications
Volume 7
Pages 10765
Date Feb 22, 2016
Journal Abbr Nat Commun
Language eng
DOI 10.1038/ncomms10765
ISSN 2041-1723
Library Catalog PubMed
Extra PMID: 26899482 PMCID: PMC4764922
Tags 3T3 Cells, Adaptor Proteins, Signal Transducing, Animals, Breast Neoplasms, Carcinoma, Ductal, Breast, Cell Line, Tumor, Female, Humans, Intracellular Signaling Peptides and Proteins, Matrix Metalloproteinase 14, Mice, Neoplasm Invasiveness, original, Receptor, ErbB-2
Date Added 2018/11/13 - 17:26:12
Date Modified 2019/05/21 - 14:43:12


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés